ppt chapter 38-1
DESCRIPTION
TRANSCRIPT
![Page 1: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/1.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Agents to Control Blood Glucose Levels
Agents to Control Blood Glucose Levels
Chapter 38
![Page 2: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/2.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Function of the Pancreas GlandFunction of the Pancreas Gland
• Endocrine Gland
– Produces hormones in the islets of Langerhans
• Exocrine Gland
– Releases sodium bicarbonate and pancreatic enzymes directly into the common bile duct to be released into the small intestine
– Neutralizes the acid chyme from the stomach and aids digestion
![Page 3: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/3.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
InsulinInsulin
• Definition
– Hormone produced by beta cells of the islets of Langerhans
• Action
– Released into circulation when the levels of glucose around these cells rise
– Stimulates the synthesis of glycogen, the conversion of lipids into fat stored in the form of adipose tissue, and the synthesis of needed proteins from amino acids
![Page 4: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/4.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Metabolic Changes Occurring When Insufficient Insulin is Released
Metabolic Changes Occurring When Insufficient Insulin is Released
• Hyperglycemia: Increased blood sugar
• Glycosuria: Sugar is spilled into the urine
• Polyphagia: Increased hunger
• Polydipsia: Increased thirst
• Lipolysis: Fat breakdown
• Ketosis: Ketones cannot be removed effectively
• Acidosis: Liver cannot remove all of the waste products
![Page 5: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/5.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Diabetes MellitusDiabetes Mellitus• Characteristics
– Complex disturbances in metabolism
– Affects carbohydrate, protein, and fat metabolism
• Clinical Signs
– Hyperglycemia (fasting blood sugar level greater than 126 mg/dL)
– Glycosuria (the presence of sugar in the urine)
![Page 6: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/6.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Disorders Associated With DiabetesDisorders Associated With Diabetes
• Atherosclerosis: Heart attacks and strokes related to the development of atherosclerotic plaques in the vessel lining
• Retinopathy: With resultant loss of vision as tiny vessels in the eye are narrowed and closed
• Neuropathies: With motor and sensory changes in the feet and legs and progressive changes in other nerves as the oxygen is cut off
• Nephropathy: With renal dysfunction related to changes in the basement membrane of the glomerulus
![Page 7: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/7.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Classifications of Diabetes MellitusClassifications of Diabetes Mellitus
• Type 1, Insulin-Dependent Diabetes Mellitus (IDDM)
– Usually a rapid onset; seen in younger people
– Connected in many cases to viral destruction of the beta cells of the pancreas
• Type 2, Non–Insulin-Dependent Diabetes Mellitus (NIDDM)
– Usually occurs in mature adults
– Has a slow and progressive onset
![Page 8: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/8.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Clinical Signs and Symptoms of Hyperglycemia
Clinical Signs and Symptoms of Hyperglycemia
• Fatigue
• Lethargy
• Irritation
• Glycosuria
• Polyphagia
• Polydipsia
• Itchy Skin
![Page 9: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/9.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Signs of Impending Dangerous Complications of HyperglycemiaSigns of Impending Dangerous
Complications of Hyperglycemia
• Fruity breath as the ketones build up in the system and are excreted through the lungs
• Dehydration as fluid and important electrolytes are lost through the kidneys
• Slow, deep respirations (Kussmaul’s respirations) as the body tries to rid itself of high acid levels
• Loss of orientation and coma
![Page 10: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/10.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
HypoglycemiaHypoglycemia
• Definition
– Blood sugar concentration lower than 40 mg/dL
• Occurrence
– Starvation
– Lowering the blood sugar too far with treatment of hyperglycemia
![Page 11: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/11.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
QuestionQuestion
Which of the following is a clinical manifestation of hyperglycemia?
A. Edema
B. Lack of thirst
C. Itchy skin
D. Hyperexcitability
![Page 12: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/12.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
AnswerAnswer
C. Itchy skin
Rationale: Clinical signs and symptoms of hyperglycemia: fatigue; lethargy; irritation; glycosuria; polyphagia; polydipsia; itchy skin
![Page 13: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/13.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Types of InsulinTypes of Insulin
![Page 14: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/14.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
InsulinInsulin
• Actions
– Hormone that promotes the storage of the body’s fuels
– Facilitates the transport of various metabolites and ions across cell membranes
– Simulates the synthesis of glycogen from glucose
– Reacts with specific receptor sites on the cells
![Page 15: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/15.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Insulin (cont.)Insulin (cont.)
• Indications
– Treatment of type 1 diabetes mellitus
– Treatment of type 2 diabetes mellitus in patients whose diabetes cannot be controlled by diet or other agents
• Pharmacokinetics
– Various insulins available are processed within the body like endogenous insulin
– Peak, onset, and duration vary based on preparation
![Page 16: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/16.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Insulin (cont.)Insulin (cont.)
• Contraindications
– There are no contraindications
• Caution
– Pregnancy and lactation
• Adverse Effects
– Hyperglycemia and ketoacidosis
![Page 17: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/17.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Insulin (cont.)Insulin (cont.)
• Drug-to-Drug Interactions
– When given with any drug that decreases glucose levels
– Beta blockers
![Page 18: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/18.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Site of Action of Drugs Used to Treat Diabetes
Site of Action of Drugs Used to Treat Diabetes
![Page 19: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/19.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
SulfonylureasSulfonylureas
• First Generation
– Associated with increase risk of cardiovascular disease
• Second Generation
– Advantage over 1st generation drugs
• Excreted in urine and bile
• Do not interact with as many protein bound drugs
• Longer duration of action
![Page 20: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/20.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Sulfonylureas (cont.)Sulfonylureas (cont.)
• Actions
– Stimulate insulin release from the beta cells in the pancreas
– They improve binding to insulin receptors
• Indications
– Adjunct to diet and exercise to lower blood glucose levels in type 2 diabetes
![Page 21: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/21.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Sulfonylureas (cont.)Sulfonylureas (cont.)
• Pharmacokinetics
– Rapidly absorbed from the GI tract and undergo hepatic metabolism
– Excreted in the urine
– Peak and duration varies with each drug
• Contraindications
– Allergy
– Diabetic complications
– Type 1 diabetes mellitus
![Page 22: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/22.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Sulfonylureas (cont.)Sulfonylureas (cont.)
• Adverse Effects
– Hypoglycemia
– GI distress
– Allergic skin reactions
• Drug-to-Drug Interactions
– Drugs that acidifies the urine
– Beta blockers
– Alcohol
![Page 23: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/23.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
QuestionQuestion
Please answer the following statement as true or false.
Second generation sulfonylureas have several advantages over first generation sulfonylureas including the fact that
they interact with more protein bound drugs.
![Page 24: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/24.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
AnswerAnswer
False
Rationale: Second generation sulfonylureas: Advantage over 1st generation drugs would be they are excreted in
urine and bile; do not interact with as many protein bound drugs; longer duration of action
![Page 25: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/25.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nonsulfonylureas Nonsulfonylureas
• Actions, Indications, Pharmacokinetics, Contraindications, Caution, Adverse Effects, Drug-to-Drug Interactions
– Vary with the drug that is given
![Page 26: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/26.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Glucose Elevating AgentsGlucose Elevating Agents• Actions
– Increase the blood glucose levels by decreasing insulin release and accelerating the breakdown of glycogen in the liver to release glucose
• Indications
– Treatment of hypoglycemia
• Pharmacokinetics
– Rapidly absorbed and distributed throughout the body
– Excreted in the urine
![Page 27: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/27.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Glucose Elevating Agents (cont.)Glucose Elevating Agents (cont.)• Contraindications
– Known allergy
– Pregnancy and lactation
• Caution
– Hepatic dysfunction or cardiovascular disease
• Adverse Effects
– GI upset
– Vascular effects
• Drug-to-Drug Interactions
– Thiazide diuretics
– Anticoagulants
![Page 28: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/28.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Use of Antidiabetic Agents Across the Lifespan
Use of Antidiabetic Agents Across the Lifespan
![Page 29: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/29.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
QuestionQuestion
Which of the following is a primary action of glucose lowering agents?
A. Accelerate the breakdown of glycogen
B. Increase insulin release
C. Improve binding to insulin receptors
D. Decrease use of incretins
![Page 30: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/30.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
AnswerAnswer
A. Accelerate the breakdown of glycogen
Rationale: The action of glucose elevating agents is to increase the blood glucose levels by decreasing insulin release and accelerating the breakdown of glycogen in the liver to release glucose.
![Page 31: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/31.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype InsulinPrototype Insulin
![Page 32: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/32.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Sulfonylureas – First Generation
Prototype Sulfonylureas – First Generation
![Page 33: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/33.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Sulfonylureas – Second Generation
Prototype Sulfonylureas – Second Generation
![Page 34: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/34.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Nonsulfonylureas Prototype Nonsulfonylureas
![Page 35: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/35.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for InsulinNursing Considerations for Insulin
• Assessment: History and Physical Exam
• Nursing Diagnosis
• Implementation
• Evaluation
![Page 36: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/36.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Oral Antidiabetic Agents
Nursing Considerations for Oral Antidiabetic Agents
• Assessment: History and Physical Exam
• Nursing Diagnosis
• Implementation
• Evaluation
![Page 37: Ppt chapter 38-1](https://reader036.vdocument.in/reader036/viewer/2022081414/54816c745906b5dc6c8b4662/html5/thumbnails/37.jpg)
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Glucose Elevating Agents
Nursing Considerations for Glucose Elevating Agents
• Assessment: History and Physical Exam
• Nursing Diagnosis
• Implementation
• Evaluation